Limits...
Renovascular and renoprotective properties of telmisartan: clinical utility.

Ladino M, Hernandez Schulman I - Int J Nephrol Renovasc Dis (2010)

Bottom Line: Chronic kidney disease (CKD) affects approximately 26 million adults in the United States and millions of others are at increased risk.Telmisartan is a long-acting ARB with pharmacological properties beyond blockade of the angiotensin II type 1 receptor, including activation of the peroxisome proliferator activated receptor-γ (PPAR-γ).This article reviews the beneficial renal and vascular protective effects of telmisartan.

View Article: PubMed Central - PubMed

Affiliation: Nephrology-Hypertension Section, Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA. ischulman@med.miami.edu

No MeSH data available.


Related in: MedlinePlus

Effects of telmisartan via blockade of the AT1 receptor.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108769&req=5

f2-ijnrd-3-033: Effects of telmisartan via blockade of the AT1 receptor.

Mentions: The importance of blood pressure control as a means to prevent development or reduce progression of cardiovascular and kidney diseases has been firmly established. Like other blockers of the AT1 receptor, telmisartan is effective in reducing blood pressure when used alone or in combination with other antihypertensives.13 Its longer half-life, lipophilicity, and ability to stimulate PPAR-γ seem to provide additional cardiovascular and renal protective properties that make it an attractive agent for global cardiovascular risk reduction (Figure 2).


Renovascular and renoprotective properties of telmisartan: clinical utility.

Ladino M, Hernandez Schulman I - Int J Nephrol Renovasc Dis (2010)

Effects of telmisartan via blockade of the AT1 receptor.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108769&req=5

f2-ijnrd-3-033: Effects of telmisartan via blockade of the AT1 receptor.
Mentions: The importance of blood pressure control as a means to prevent development or reduce progression of cardiovascular and kidney diseases has been firmly established. Like other blockers of the AT1 receptor, telmisartan is effective in reducing blood pressure when used alone or in combination with other antihypertensives.13 Its longer half-life, lipophilicity, and ability to stimulate PPAR-γ seem to provide additional cardiovascular and renal protective properties that make it an attractive agent for global cardiovascular risk reduction (Figure 2).

Bottom Line: Chronic kidney disease (CKD) affects approximately 26 million adults in the United States and millions of others are at increased risk.Telmisartan is a long-acting ARB with pharmacological properties beyond blockade of the angiotensin II type 1 receptor, including activation of the peroxisome proliferator activated receptor-γ (PPAR-γ).This article reviews the beneficial renal and vascular protective effects of telmisartan.

View Article: PubMed Central - PubMed

Affiliation: Nephrology-Hypertension Section, Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, FL, USA. ischulman@med.miami.edu

No MeSH data available.


Related in: MedlinePlus